News

May 16-18, 2024— the 23rd China Biological Products Annual Conference was held in Guangzhou, China. Dr. Li Aiqun, Director of QC, Frontera Therapeutics, was invited to participate in the symposium of “Immune Cells, Stem Cells and Gene Therapy” and focused on “Quality Control of rAAV Gene Therapy Products: Challenges of Next Generation Sequencing and Residual DNA […]

May 6, 2024–Frontera Therapeutics is pleased to announce significant advancements in our clinical study of FT-002, presented at Retinal Cell and Gene Therapy Innovation Summitin the United States on May 3, 2024. Professor Sui Ruifang, from Peking Union Medical College Hospital, was invited to present the clinical results, titled “Preliminary safety and efficacy of an […]

Boston, MA, USA – April 22, 2024. Frontera Therapeutics is excited to announce its participation in several esteemed conferences in May 2024, where it will present groundbreaking research across multiple therapeutic areas, including ophthalmology, blood and cardiovascular diseases.  The conferences are the 2024 Retinal Cell and Gene Therapy Innovation Summit, the 2024 American Ophthalmology Congress, […]

Boston, MA, USA – April 1, 2024. The 7th Gene Therapy for Rare Disorder 2024 took place in Boston, MA from March 26 to 29, 2024. Dr. Hongxiang Lu, Senior Vice President of Frontera Therapeutics, was invited to participate in the panel discussion on “Gene Drug Manufacturing” and gave a keynote presentation on “Case Studies […]

Boston, USA – March 18, 2024 – Frontera Therapeutics, a leading biotechnology company committed to advancing gene therapy drugs to address unmet medical needs worldwide, is delighted to announce its participation in the upcoming 7th Gene Therapy for Rare Disorders 2024 Conference in Boston, USA. Dr. Robert Lu, Senior Vice President of Frontera, has been […]

BEDFORD, Mass., and Suzhou, China, January 23, 2024 — Frontera Therapeutics announces that its pioneering AAV gene therapy product, FT-002, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of Inherited Retinal Dystrophies (IRD) caused by RPGR gene variants. About Orphan Drug Designation Orphan Drug Designation, granted […]

Hongkong, China, Decemeber 8th, 2023 – Preliminary clinical study results of FT-002, an AAV gene therapy treatment of Frontera Therapeutics, a potential first in class therapy for the treatment of XLRP, were reported at the 16th Asia-Pacific Vitreo-Retina Society, APVRS, 2023). Professor Sui Ruifang from Peking Union Medical College Hospital was invited to participate in […]

Beijing, China, Decemeber 3rd, 2023 – Frontera Therapeutics (Suzhou) Co., Ltd. (hereinafter referred to as Frontera Therapeutics) convened a meeting in Beijing on December 3 to conclude the Phase I clinical study of FT-001, and initiate the Phase II clinical study. The meeting was attended by esteemed clinical experts, including Professor Sui Ruifang, Professor Yu […]

BEDFORD, Mass., and SHANGHAI, China, Nov 6th, 2023 – Frontera Therapeutics (Suzhou) Co., Ltd (referred to as Frontera) announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has given clearance of the Investigational New Drug (IND) application to begin a clinical trial of an innovative gene therapy drug, FT-002, for […]

BEDFORD, Mass., and SHANGHAI, China, July 12, 2023 – An application for an investigational study in human patients with FT-004, an innovative gene therapy drug independently developed by Frontera Biotechnology (Suzhou) Co., Ltd. (hereinafter referred to as “Frontera Biotechnology”), was approved by the Center for Drug Evaluation (CDE) of China National Medical Products Administration for […]